PT Itama Ranoraya Tbk

Jakarta Stock Exchange IRRA.JK

PT Itama Ranoraya Tbk EBITDA for the year ending December 31, 2023: USD 2.13 M

PT Itama Ranoraya Tbk EBITDA is USD 2.13 M for the year ending December 31, 2023, a -57.92% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

PT Itama Ranoraya Tbk EBITDA for the year ending December 31, 2022 was USD 5.05 M, a -53.98% change year over year.
PT Itama Ranoraya Tbk EBITDA for the year ending December 31, 2021 was USD 10.98 M, a 91.16% change year over year.
PT Itama Ranoraya Tbk EBITDA for the year ending December 31, 2020 was USD 5.74 M, a 73.02% change year over year.
PT Itama Ranoraya Tbk EBITDA for the year ending December 31, 2019 was USD 3.32 M, a 7.56% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

Jakarta Stock Exchange: IRRA.JK

PT Itama Ranoraya Tbk

CEO	Mr. Heru Firdausi Syarif
IPO Date	Oct. 15, 2019
Location	Indonesia
Headquarters	MT. Haryono Square
Employees	229
Sector	Health Care
Industries Medical Instruments Pharmaceuticals

Description

PT Itama Ranoraya Tbk engages in the procurement of health goods in Indonesia. It offers non-electromedical sterile medical devices, in vitro diagnostic products, and other products. The company's products include ADS syringes, blood screening machines and reagents, apheresis machines, blood processing machines, rapid test products, vaccine refrigerators, masks, products for surgery in hospitals, ultrasound, and health supplements. It is also involved in building and office space rental business. The company was founded in 1988 and is headquartered in Jakarta Timur, Indonesia. PT Itama Ranoraya Tbk is a subsidiary of PT Global Dinamika Kencana.

Key trends

Past 5 years